Glaucoma Research Center, Montchoisi Clinic, Swiss Visio Network, Lausanne, Switzerland.
Department of Ophthalmology, University of Colorado School of Medicine, Denver, CO.
J Glaucoma. 2020 Jan;29(1):11-14. doi: 10.1097/IJG.0000000000001394.
The XEN gel stent is currently the only minimally invasive glaucoma surgical device that targets the subconjunctival outflow pathway through an ab interno placement. It has demonstrated a significant intraocular pressure (IOP)-lowering potential and a favorable safety profile compared with traditional filtering surgery. However, despite a less invasive approach, the presence of a filtering bleb inevitably implies some risk of complications. The most commonly reported bleb-related complication, with rates as high as 45%, is bleb fibrosis associated with raised IOP. To restore filtration in those failing blebs, needling revision is considered the procedure of choice. In this study, we present the results of mitomycin C-augmented needling after XEN implantation.
This was a prospective, interventional study, conducted at a single tertiary glaucoma center. Fifty-one eyes of 51 patients with raised IOP associated with either a fibrotic or shallow bleb or increased vascularity following XEN gel stent implantation at the investigation site between January 2015 and June 2016 were enrolled in this study. Patients with other identified causes of filtration failure (stent malposition, internal ostium obstruction, retained viscoelastic) were excluded. Included patients who underwent mitomycin C-augmented needling revision, and follow-up examinations were conducted at 1 day, 1 week, and 1, 3, 6, 12, 18, and 24 months. The primary outcome was the magnitude of IOP reduction following needling revision at the last follow-up visit. Secondary outcome measures were the number of needling procedures carried out in all patients, the rate of patients requiring further filtering surgery following needling revision, and the rate of intraoperative and postoperative complications associated with needling revisions.
The average age was 74.4±9.6 years; 66.7% (n=34) were female individuals. Primary open-angle glaucoma was the most common diagnosis (n=21, 41.2%). A total of 78 needling procedures were performed over the 24-month follow-up. Overall 20 of 51 eyes (39.2%) required >1 needling revision, and 14 eyes (24.5%) eventually required reoperation to maintain IOP within their desired target range. Before XEN implantation, mean preoperative IOP was 22.3±8.2 mm Hg and decreased to 14.1±8.0 mm Hg at day 1 postoperatively (-36.8%). The last measured IOP before the first needling revision was on average 23.6±8.9 mm Hg, which reduced to a mean 12.1±4.2 mm Hg at the first postrevision appointment (-48.7%). At the last follow-up appointment, on average 17.0±7.0 months after the first needling, the mean IOP was 14.3±4.1 mm Hg (-35.9% and -39.4% from preoperative and prerevision baselines, respectively). Complications associated with needling revisions were partial amputation of the XEN implant during needling (n=2, 3.9%), hypotony with choroidal detachment (n=1, 2%), and failure to achieve target IOP requiring subsequent surgery (n=14, 27.5%). No association was found between any of the recorded characteristics and the number of needling revisions performed or their outcomes.
The present study shows that needling revision following XEN gel stent implantation is a relatively safe and efficient intervention to restore filtration in failing blebs, with a significant and durable IOP-reduction potential.
XEN 凝胶支架是目前唯一一种通过经内眼入路靶向结膜下流出途径的微创青光眼手术设备。与传统滤过性手术相比,它具有显著的降眼压潜力和良好的安全性。然而,尽管采用了微创方法,但滤过泡的存在不可避免地存在一些并发症的风险。最常报告的与滤过泡相关的并发症,发生率高达 45%,是与眼压升高相关的滤过泡纤维化。为了恢复失败的滤过泡的滤过功能,需要进行针刺修复,这被认为是首选的治疗方法。在这项研究中,我们报告了 XEN 植入后应用丝裂霉素 C 增强针刺修复的结果。
这是一项前瞻性、干预性研究,在一家三级青光眼中心进行。2015 年 1 月至 2016 年 6 月,在研究现场,51 例患者的 51 只眼因 XEN 凝胶支架植入后出现纤维性或浅滤过泡或增加血管化而导致眼压升高,接受了丝裂霉素 C 增强针刺修复。排除其他确定的滤过失败原因(支架位置不当、内口阻塞、残留粘性)的患者。包括接受丝裂霉素 C 增强针刺修复的患者,并在 1 天、1 周、1、3、6、12、18 和 24 个月进行随访检查。主要终点是最后一次随访时针刺修复后的眼压降低幅度。次要终点是所有患者进行的针刺次数、需要进一步滤过手术的患者比例,以及与针刺修复相关的术中及术后并发症的发生率。
平均年龄为 74.4±9.6 岁;66.7%(n=34)为女性。最常见的诊断是原发性开角型青光眼(n=21,41.2%)。共进行了 78 次针刺治疗,随访时间为 24 个月。总体而言,20 只眼(39.2%)需要>1 次针刺修复,14 只眼(24.5%)最终需要再次手术以维持眼压在预期目标范围内。在 XEN 植入前,平均术前眼压为 22.3±8.2 mm Hg,术后第 1 天降至 14.1±8.0 mm Hg(降低 36.8%)。第一次针刺修复前的最后一次测量眼压平均为 23.6±8.9 mm Hg,第一次修复后预约时降至 12.1±4.2 mm Hg(降低 48.7%)。在第一次针刺修复后的第 17.0±7.0 个月(平均 17.0±7.0 个月)的最后一次随访时,平均眼压为 14.3±4.1 mm Hg(与术前和修复前基线相比分别降低了 35.9%和 39.4%)。与针刺修复相关的并发症包括针刺过程中 XEN 植入物部分截断(n=2,3.9%)、低眼压伴脉络膜脱离(n=1,2%)和未能达到目标眼压需要后续手术(n=14,27.5%)。未发现任何记录的特征与针刺次数或结果之间存在相关性。
本研究表明,XEN 凝胶支架植入后进行针刺修复是一种相对安全有效的干预措施,可以恢复失败的滤过泡的滤过功能,具有显著而持久的降眼压潜力。